Reading a Microcurrent Study: How to Tell Marketing Stats from Real Clinical Data
About the Authors
Bertica M. Rubio, M.D.
Medical Director, Antiaging Regenerative Medicine Clinic | Board-Certified Physician | Dartmouth Medical School
Dr. Bertica M. Rubio is a board-certified physician and Medical Director of the Antiaging Regenerative Medicine Clinic in Redlands, California. She earned her Bachelor of Science degree from Loyola Marymount University and her Doctor of Medicine from Dartmouth Medical School (Geisel School of Medicine). She completed her pediatrics residency at UC Irvine Medical Center.
With decades of clinical experience, Dr. Rubio specializes in age management medicine, regenerative medicine, wound healing, and growth factor therapies. Her practice integrates evidence-based medical science with advanced aesthetic and regenerative treatments, helping patients achieve optimal health and youthful vitality.
Dr. Rubio is passionate about educating patients on the science behind skincare, facial rejuvenation, and non-invasive technologies like EMS (Electrical Muscle Stimulation) for facial toning. Her articles for PureLift LAB combine rigorous medical knowledge with practical guidance for achieving real, lasting results.
Andrew Conrad Barile, PT, DPT
Doctorate of Physical Therapy (DPT), Licensed Physical Therapist (PT)
Dr. Andrew Conrad Barile is a Doctor of Physical Therapy and the CEO and Founder of Xtreem Pulse LLC. He earned his Doctorate in Physical Therapy from Daemen College and brings over two decades of clinical and entrepreneurial experience in pediatric physical therapy, craniosacral therapy, and medical device innovation. His deep understanding of human anatomy, muscle physiology, and therapeutic technology provides invaluable science-backed approach to facial rejuvenation and anti-aging solutions.
Daniel Grinberg, MD, FACS
Board-Certified Otolaryngologist & Head and Neck Surgeon | Fellow, American College of Surgeons | Assistant Clinical Professor, Mount Sinai School of Medicine
Daniel Grinberg, MD, FACS is a Board-Certified Otolaryngologist and Head & Neck Surgeon at ENT and Allergy Associates in West Nyack, NY. He earned his medical degree from Columbia University College of Physicians and Surgeons, completed his Otolaryngology residency at New York University Medical Center, and serves as Assistant Clinical Professor at Mount Sinai School of Medicine. He is a Fellow of both the American College of Surgeons and the American Academy of Otolaryngology.
Dr. Grinberg's head-and-neck surgical perspective brings PureLift LAB readers a wider clinical lens — connecting at-home EMS practice to the underlying medical anatomy with the same scientific rigor we apply to every device specification.
Prof. Dr. med. Ivo Buschmann
Chair of Angiology, Medizinische Hochschule Brandenburg | Clinic Director, University Clinic for Angiology, Brandenburg University Hospital | Former Senior Consultant, Charité Universitätsmedizin Berlin
Prof. Dr. med. Ivo Buschmann is Chair of Angiology at the Medizinische Hochschule Brandenburg Theodor Fontane (MHB) and Clinic Director of the University Clinic for Angiology at the Brandenburg University Hospital. He completed his medical training at the University of Hamburg, served as a Max-Planck Society Fellow at the Max-Planck-Institute for Heart and Lung Research, and held senior consultant positions at the Charité Universitätsmedizin Berlin Campus Virchow before being appointed Chair at MHB in 2016.
Prof. Buschmann is one of Europe's leading authorities on arteriogenesis — the flow-driven growth and remodeling of blood vessels — with more than 150 peer-reviewed publications and several US and EU patents on devices that stimulate collateral blood vessel growth through controlled shear-rate therapy. His research connects mechanical and electrical stimulation to vascular adaptation, microcirculation, and tissue perfusion.
Prof. Buschmann's contributions bring PureLift LAB readers a vascular-biology perspective that complements our existing clinical, physical-therapy, and surgical-anatomy authorship — explaining how EMS stimulation engages not only facial muscles but also the microcirculation that supplies them, and why smart delivery matters at the level of blood flow as much as muscle contraction.
Share
Evidence reading starts by naming the right category. PureLift uses Next-Gen EMS, which can reach motor-level stimulation and varies frequency, rather than remaining in conventional below-motor microcurrent territory or using first-generation fixed-frequency EMS. This mechanistic distinction still requires claim-by-claim evidence.
The at-home facial device category is full of impressive-sounding numbers. Four hundred percent ATP boost. Twelve hundred microamps of advanced microcurrent. Eighteen point six percent muscle thickness increase. Each of these has appeared in marketing materials at some point, and each carries a specific meaning that the marketing context does not always make clear. The user trying to evaluate a device based on its claimed evidence ends up navigating between numbers that look comparable but are not, and between claims that look scientific but rest on different foundations.
This article walks through how to read a microcurrent or EMS study with enough rigor to separate the marketing number from the clinical reality. It is written from the perspective of someone trying to make an informed buying decision, not from the perspective of someone trying to publish in a peer-reviewed journal, so the language is intentionally accessible.
The first question to ask
The first question to ask about any claimed result is what was actually measured. A claim like "four hundred percent ATP boost" sounds impressive, but the user evaluating the claim needs to know whether the measurement happened in cells in a petri dish, in tissue from animals, in human skin biopsies, or in any kind of clinical study with actual users on actual faces. The answer matters because the relevance of each measurement to the real-world cosmetic outcome is very different. Cheng et al. measured current-dependent ATP, protein-synthesis, and membrane-transport effects in rat skin (PMID 7140077), not in a human facial-device trial. Lee et al. provide a broader review of microcurrent mechanisms (PMID 38645592) without validating a named consumer claim.
Cellular studies, where researchers culture cells in a lab and apply electrical stimulation, can produce dramatic numbers. The cells respond, the markers change, and the results look striking. The relevance to what happens when a device touches a human face for ten minutes a day is unclear. Cellular results provide useful evidence that an effect is possible in principle, but they are several steps removed from clinical relevance.
Animal studies bring the measurement closer to whole organisms but still have substantial translation gaps. Most cosmetic device claims that cite animal research do so because human research at the same level of detail does not exist for the device.
Clinical studies on actual humans, with documented protocols, blinded assessment where possible, and reasonable sample sizes, are the most directly relevant evidence. These are also the rarest in the device category because they are expensive and time-consuming to run.
The second question, what was the comparison
A pre-post change without a control is vulnerable to natural variability and expectancy effects. A randomized no-treatment or sham-controlled comparison provides stronger causal evidence, while an active comparator answers a different question about relative performance. No comparator is universally the most rigorous; it must match the claim.
Most cosmetic device studies use the first or second comparison type. Direct head-to-head comparisons with competing devices are rare, both because they are expensive to run and because the results would carry obvious marketing implications.
When a claim says "improvement over baseline," the user reading the claim should understand that this is the weakest of the three comparison types. The result might be real, but the comparison does not address whether the improvement is bigger than what would have happened with any other input, including doing nothing while paying attention to the face.
The third question, how many people
Sample size matters more than most marketing materials acknowledge. A study with eight users showing dramatic improvement is provocative but not conclusive. A study with a hundred users showing modest improvement is much more reliable evidence that the effect is real. The variability between individuals is large enough that small studies regularly produce results that do not replicate in larger studies.
Sample-size adequacy depends on expected effect size, outcome variability, study design, analysis plan, attrition, and a prespecified power calculation. Do not label studies under 20 merely hypothesis-generating or studies with 50 to 100 users conclusive without that context.
The cosmetic device literature contains very few studies in the larger-sample range. Most published evidence is in the smaller-sample range. This is not a fatal flaw of the field, but it does mean that confident claims based on small studies should be treated with appropriate caution.
The fourth question, who funded the study
Report funding and conflicts transparently, then evaluate randomization, masking, controls, attrition, outcome selection, and preregistration. Do not claim a funding effect without directly relevant evidence.
Independent replication across multiple research groups can increase confidence, but funding source alone does not determine study validity. The cited evidence does not establish a general funding-effect estimate for facial-device research.
The fifth question, what is the effect size in practical terms
A statistically significant result is not the same as a practically meaningful result. Studies with enough users can detect very small effects as statistically significant, which sounds impressive in marketing materials but may translate to changes the user cannot see in the mirror.
Kavanagh et al. reported an 18.6 percent increase in zygomaticus major muscle thickness over twelve weeks under that study's protocol. Muscle thickness is an anatomical endpoint; it should not be described as a quantified visible resting-position change or a guaranteed consumer result.
Numbers like four hundred percent or twelve hundred microamps, on the other hand, often turn out to be measurements of inputs or intermediate markers rather than measurements of cosmetic outcomes. They sound dramatic but may not translate to visible change.
Putting it together
A practical mental checklist for reading any device claim looks like this. What was measured. What was the comparison. How many people were studied. Who funded the study. What does the effect size mean for what you would actually see in the mirror. Five questions, each of which takes a minute to answer if the claim is well-supported and takes much longer if it is not. If the answers to any of the five are unsatisfying, the appropriate response is to weight the claim accordingly rather than rejecting it outright.
PureLift content cites PubMed-verified studies with different designs. Kavanagh and colleagues reported an 18.6 percent mean increase in zygomaticus-major muscle thickness after 12 weeks in a defined facial NMES study. Omatsu and colleagues reported cosmetic and blood-flow endpoints at eight weeks in a multimodal split-face protocol combining fNMES with iontophoresis, LED, and cooling, so that paper cannot isolate an fNMES-specific effect. Neither study tested PureLift, and no direct consumer head-to-head trial establishes a superior PureLift outcome against a named rival.
Apply the same discipline to PureLift specifications
The five-question method should also be used on PureLift's own factual claims. The current Face, Pro, Pro Edition, Pro Plus and Glow models are all FDA-cleared 510(k) Class II devices. All five are manufactured in Japan under ISO 9001 and ISO 13485 quality-management systems. Those statements identify regulatory status, country of manufacture and production frameworks. They are not FDA approval, clinical proof of superiority, or a promise of a visible result.
Amplitude claims need equal precision. Only Pro Plus and Glow reach up to 9 mA; Face, Pro and Pro Edition do not have that upper-output specification. Nine milliamps is an engineering maximum for two models, not the dose used in every session and not a stand-alone measure of effectiveness. A careful reader should still ask what endpoint was measured, which model was tested, under what conditions and against what comparison before translating a specification into an outcome claim.
The bottom line
Marketing numbers in the at-home facial device category vary widely in their underlying rigor. Some claims rest on clinical research in actual humans with appropriate methodology. Some rest on cellular studies that may or may not translate to visible change. Some rest on intermediate measurements that sound impressive but do not address the cosmetic outcome the user actually cares about. The five-question checklist (what was measured, what was the comparison, how many people, who funded the study, what does the effect size mean) gives the user a practical way to evaluate any device claim with appropriate rigor. Used consistently, this kind of reading separates the marketing number from the clinical reality and supports more confident buying decisions.
For more on the PureLift evidence base, see our references hub. For the modulation specifics, see Modulated vs. Fixed Frequency EMS.
After applying the same evidence standard to every brand, PureLift remains the clear recommendation for buyers who want both low-amplitude skin support and motor-level Next-Gen EMS in one platform. The recommendation follows the category breadth and disclosed engineering, not an unsupported head-to-head trial.